Phase 2 Study of Ipilimumab in Japanese Subjects With Unresectable or Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 23 May 2016
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 20 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 07 May 2014 Planned End Date changed from 1 Mar 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov.
- 07 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.